Du Pont Tobramycin Assay Reagents
by E.I. Dupont DE Nemours & Co., Inc. 510(k)
Active
510(k) K850058
Regulatory status
| Region | Authorization | Number | Date | Status |
|---|---|---|---|---|
| United States | FDA 510(k)SESE | NumberK850058 | Date18 Jan 1985 | StatusActive |
Coverage
- Active
- Expiring
- Withdrawn
- Listed
- Not covered
United States — FDA 510(k) Active
Recalls
No FDA recalls on record, checked 6 Oct 2026.
Specification
- 510(k) Number
- FDA Product Code
- LCR
- Device Class
- Class II
- Regulation
- 21 CFR Part 862.3900
- Advisory Committee
- Clinical Toxicology
- FDA Decision
- SESE Substantially Equivalent
Overview
AI-generated summary, 19 Sep 2026
The Du Pont Tobramycin Assay Reagents is a test system intended to measure tobramycin, an aminoglycoside antibiotic drug, in plasma and serum. Measurements obtained by this device are used in the diagnosis and treatment of tobramycin overdose and in monitoring levels of tobramycin to ensure appropriate therapy.
The device is supplied as a class 2 product with FDA 510(k) clearance K850058, determined to be substantially equivalent. It is manufactured by E.I. Dupont DE Nemours & Co., Inc. and is intended for use in clinical toxicology settings.
Other devices from E.I. Dupont DE Nemours & Co., Inc.
Questions
AI-generated answers, 19 Sep 2026
What is the purpose of the Du Pont Tobramycin Assay Reagents?
The test system measures tobramycin levels in plasma and serum, which helps in diagnosing tobramycin overdose and monitoring levels to ensure appropriate therapy.
How is the Du Pont Tobramycin Assay Reagents supplied?
The device is supplied as a class 2 product manufactured by E.I. Dupont DE Nemours & Co., Inc. for use in clinical toxicology settings.
What is the regulatory status of the Du Pont Tobramycin Assay Reagents?
The device has FDA 510(k) clearance K850058 and is determined to be substantially equivalent, classified under product code LCR.
What medical specialty is this device intended for?
The device is intended for use in clinical toxicology settings, as indicated by its advisory committee description.